Alerts will be sent to your verified email
Verify Email
EMMESSA
|
Emmessar Biotech&Nut
|
Hamps Bio
|
Parmax Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
13.7 % | 17.75 % | -1624.87 % |
|
5yr average Equity Multiplier
|
1.24 | 2.66 | 46.04 |
|
5yr Average Asset Turnover Ratio
|
0.36 | 1.39 | 0.95 |
|
5yr Avg Net Profit Margin
|
71.53 % | 5.48 % | -9.48 % |
|
Price to Book
|
2.59 | 0.0 | 0.0 |
|
P/E
|
63.18 | 38.82 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
68.18 Days | 10.22 Days | -161.05 Days |
|
Inventory Days
|
62.21 Days | 38.15 Days | 73.65 Days |
|
Days Receivable
|
10.88 Days | 49.29 Days | 40.27 Days |
|
Days Payable
|
199.95 Days | 79.37 Days | 328.05 Days |
|
5yr Average Interest Coverage Ratio
|
815.2 | 3.3 | 1.16 |
|
5yr Avg ROCE
|
19.97 % | 22.28 % | -9.94 % |
|
5yr Avg Operating Profit Margin
|
-101.39 % | 15.08 % | 3.93 % |
|
5 yr average Debt to Equity
|
0.0 | 1.2 | 17.42 |
|
5yr CAGR Net Profit
|
0.0 | 33.03 % | n/a |
|
5yr Average Return on Assets
|
10.86 % | 7.45 % | -6.43 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
59.53 % | 71.99 % | 30.8 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
1.02 % | 0.0 | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Emmessar Biotech&Nut
|
Hamps Bio
|
Parmax Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|